Clinical Trials · NCT02212197
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Camurus AB
- Enrollment
- 51
- Start date
- Sep 2014
- Locations
- 7 sites, Finland, Hungary
- Primary endpoint
- Observed Maximum Serum Leuprolide Concentration (Cmax) for Dose 1 and Dose 3